Company Info

Oneness Biotech was established in 2008 and listed on the Taiwan TPEx market in September 2011. The company is dedicated to the research and development of First-in-Class and Best-in-Class global innovative drugs and medical devices, focusing on the treatment of wounds, chronic skin diseases, immunological and metabolic disorders, as well as the development of novel small nucleic acid new drugs.

1. ON101: Dual Pathway as a Drug and a Medical Device
   • FESPIXON^® is the world’s first new drug approved for the treatment of diabetic foot ulcers (DFU). It has obtained regulatory approvals in Taiwan, Singapore, Malaysia, mainland China, and Indonesia.
   • Bonvadis^® is an innovative wound care medical device that has obtained marketing authorization in the United States, Saudi Arabia, Australia, and New Zealand.
2. FB825: A new anti-allergic antibody drug which has been licensed to the international pharmaceutical company is currently undergoing two Phase II clinical trials for atopic dermatitis and asthma.
3. FB704A: A novel anti-IL6 full-human antibody drug, independently developed using the “full-human antibody library” platform, has received US FDA Phase II clinical trial approval and shows the potential in treating rheumatoid arthritis and inhibiting tumor angiogenesis.
4. SNS812: The world’s first broad-spectrum anti-COVID small nucleic acid drug whose Phase II clinical data shows that, with a good safety profile, over 90% of patients achieve viral negativity within three days.
5. SNS851: An innovative new weight-loss drug targeting liver mitochondria is currently under clinical development and has potential applications in metabolic diseases such as obesity, diabetes, hypercholesterolemia (high cholesterol), and fatty liver disease.

Driven by innovation and combined with global strategic partnerships, Oneness Biotech continues to translate its R&D achievements into international markets and to improve human health through innovative medical solutions.